Gain TherapeuticsGANX
13F holders, Q1 2024 (March 31)26holders
4famous investors
$3.77avg. 13F price*
At the end of Q1 2024, 26 institutions reported holding Gain Therapeutics Inc. (GANX) in their 13F filings. The largest holders were Greenlight Capital (DME Capital Management) ($2.1M), Raymond James & Associates ($980K) and Royal Bank of Canada ($937K). 4 famous investors held it, including David Einhorn (0.1% of Greenlight Capital (DME Capital Management)'s portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Gain Therapeutics Inc.
- CUSIP
- 36269B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $199K |
| Exits | 3 | $122K |
Ownership 26 holders
| Greenlight Capital (DME Capital Management) | 0.10% | Reduce -3.8% | 566,130 | $2.1M |
| Raymond James & Associates | 0.00% | Add +993.1% | 260,019 | $980K |
| Royal Bank of Canada | 0.00% | Add +24.1% | 248,500 | $937K |
| Geode Capital Management, LLC | 0.00% | Add +16.9% | 177,091 | $668K |
| Vanguard Group Inc. | 0.00% | Add +35.0% | 119,364 | $450K |
| CM Management, LLC | 0.28% | No change | 90,000 | $339K |
| BlackRock Inc. | 0.00% | Add +173.1% | 75,398 | $284K |
| Renaissance Technologies | 0.00% | Add +9.1% | 46,700 | $176K |
| Northern Trust Corp. | 0.00% | Add +6.8% | 46,486 | $175K |
| Millennium Management | 0.00% | Add +248.0% | 44,416 | $167K |
| Susquehanna International Group, LLP | 0.00% | Add +24.8% | 43,062 | $162K |
| Prelude Capital Management, LLC | 0.01% | Reduce -38.4% | 35,820 | $135K |
| State Street Corp. | 0.00% | New | 30,837 | $116K |
| Bridgeway Capital Management, LLC | 0.00% | Reduce -34.9% | 30,000 | $113K |
| Simplex Trading, LLC | 0.00% | New | 17,983 | $67K |
| UBS Group AG | 0.00% | Reduce -38.1% | 8,673 | $33K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -5.3% | 4,632 | $17K |
| Creekmur Asset Management LLC | 0.01% | No change | 4,440 | $17K |
| Citadel Advisors | 0.00% | Reduce -93.5% | 4,223 | $16K |
| Wells Fargo & Company | 0.00% | Add +0.8% | 3,756 | $14K |
| Bank of America Corp. | 0.00% | New | 3,375 | $13K |
| Morgan Stanley | 0.00% | No change | 2,800 | $11K |
| Group One Trading LLC | 0.00% | Reduce -49.2% | 2,001 | $8K |
| HM Payson & Co. | 0.00% | No change | 1,000 | $4K |
| Citigroup Inc. | 0.00% | New | 684 | $3K |
| NewEdge Advisors, LLC | 0.00% | New | 225 | $848 |
"% of holder's portfolio" is GANX's weight in each manager's 13F, not the share of Gain Therapeutics Inc. the manager owns.